asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Amazon miniTV presents Sisterhood: A heartwarming tale of friendship, growth, and self-discovery; Trailer out now!

by asianprimenews0529

Mumbai, 11 June 2024:  – Amazon miniTV, Amazon’s free video streaming service, today announced its upcoming series Sisterhood, a captivating drama set in the century-old all-girls convent school, S.I.S.T.R.S., by unveiling its enthralling trailer. Showcasing a tantalising glimpse into the emotional and engaging world of Sisterhood, the trailer is filled with heartfelt moments and relatable experiences. The series delves into the lives of students at an all-girls convent school, chronicling their journey from childhood through adolescence; and their transition to becoming young women. Featuring a stellar cast, including Anvesha Vij, Nitya Mathur, Nidhi Bhanushali, and Bhagyashree Limaye, Sisterhood will stream exclusively on Amazon miniTV for free from 13th June.

The riveting trailer gives a sneak peek into the renowned institution of S.I.S.T.R.S., a school rich in history and tradition that has been home to generations of young girls. Following the journey of four friends – Zoya, Nikita, Ann and Gargee, the series highlights the strength of their bonds and their unwavering support for one another. As these girls navigate the complexities of school life, the narrative vividly portrays that a school is not merely built from bricks and mortar but is shaped by the countless emotions and experiences of its students. Embarking on a journey of friendship, self-discovery, and adventures, these girls traverse a spectrum of emotions and experiences, from joy, betrayal, and infatuation to competition, quarrels, and misunderstandings.

Amogh Dusad, Head of Content, Amazon miniTV, shared, “We are delighted to present Sisterhood on Amazon miniTV as we continue to deliver on our commitment of offering diverse and relatable content to audiences across the country. This series beautifully captures the complexities of adolescent life set against the backdrop of an all-girls convent school. We take pride in presenting a series that celebrates the power of friendship, explores the nuances of growing up, and delves into the unique experiences that shape us.”

“Sisterhood exemplifies our commitment to producing content that deeply resonates with our viewers. The series authentically portrays the intricacies of female friendships and the path to self-discovery. We’ve always strived to create content that explores the multifaceted nature of human relationships and experiences. Through our partnership with Amazon miniTV, we are excited to share this compelling story with the audience, inviting them to embark on a soulful journey into the lives of the young women of S.I.S.T.R.S.,” shared Shreyansh Pandey, Head, TVF Originals and Executive Producer on Sisterhood.

Reflecting on portraying the character of Gargee in the series, Nidhi Bhanushali expressed, “Bringing Gargee to life in Sisterhood has been a fulfilling experience. Her journey is one of self-discovery and resilience as she grapples with the complexities of a new environment and carving out her identity. Coming from a different background than her peers, she brings a unique perspective to S.I.S.T.R.S., challenging traditional norms. Portraying Gargee has been both challenging and rewarding, and I can’t wait for audiences across India to join her on this emotional rollercoaster only on Amazon miniTV.”

Step into the hallowed halls of S.I.S.T.R.S. and experience the enduring power of friendship with Sisterhood, streaming exclusively on Amazon miniTV for free from 13th June within Amazon’s shopping app, on Prime Video, Fire TV, Smart TVs, or download the app from Play Store.

Trailer Link: https://youtu.be/UmPZqzLZFHI?feature=shared

XXX

About Amazon miniTV  

Amazon miniTV is a free video streaming service available on Amazon’s shopping app, Fire TV and on Play Store, provides high quality entertainment, which you can watch anytime, anywhere. Always Entertaining. Always Free.

●   Exclusive shows and videos: Amazon miniTV is home to a cherry-picked collection of fresh, incredible and engaging stories and titles across multiple genres ranging from webseries, award-winning short films, reality shows. These include popular titles like Half CA, Love Adhura, Badtameez Dil, Hunter, Half Love Half Arranged, Yeh Meri Family, Rakshak – India’s Braves, Physics Wallah, Rafta Rafta, Case Toh Banta Hai, DehatiLadke, Sixer, Ishq Express, Highway Love, Gutar Gu, Crushed, Playground, among others. The content has been carefully curated to suit the varying entertainment preferences of today’s viewers.

●   No Paid Subscription required: Amazon miniTV is absolutely free!

Instant access: Amazon miniTV is present on Amazon’s shopping app, which is India’s most trusted and largest online store. Just download the Amazon shopping app, click or search for ‘miniTV’ to view from thousands of titles available. Want to watch on the big screen? Then visit www.amazon.in on your laptop and click on Amazon miniTV or on Fire TV. You can now also download the Amazon miniTV app on Play Store.

Industry recognition: Amazon miniTV’s content has received a lot of love from fans and the industry.  Titles such as Physicswallah, Highway Love, Dehati Ladke, Hustlers, Crushed, Hunter, and Half CA have featured by Ormax in the ‘top 10 webseries’ list; our short film Shimmy won the People’s Choice Award for Best Actor and Critic’s Choice Award for Best Actor (Pratik Gandhi); Clean won best short film at IWM Buzz Awards 2022; Yatri Kripya DhyanDe was adjudged the best short film by Indian Television Academy; as our most loved high school drama Crushed was nominated at the 2022 Filmfare OTT Awards, to name a few.

About Amazon.in

The Amazon.in marketplace is operated by Amazon Seller Services Private Ltd, an affiliate of Amazon.com, Inc. (NASDAQ: AMZN). Amazon.in offers a single destination to customers to shop for millions of products, make payments with Amazon Pay, and watch free entertainment content with Amazon miniTV.

Amazon is guided by four principles: customer obsession, passion for invention, commitment to operational excellence, and long-term thinking. Amazon Prime, Fulfilment by Amazon, AWS, Kindle, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Share

Related posts

SRI: The Inspiring Journey of Srikanth Bolla’ is all set to premiere on 17th May 2024

asianprimenews

Sabre announces agreement with Capillary Technologies to help airlines and hoteliers delight travelers through next-generation customer loyalty programs

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews